Matthew Judson is a research associate in the UNC Neuroscience Center at the University of North Carolina at Chapel Hill.
Matthew Judson
Research associate
University of North Carolina at Chapel Hill
From this contributor
Angelman syndrome: Bellwether for genetic therapy in autism
It is not a matter of whether there will be clinical trials of genetic therapy for Angelman syndrome, but when.
Angelman syndrome: Bellwether for genetic therapy in autism
By
Matthew Judson, Benjamin Philpot
16 October 2018 | 6 min read
Insights for autism from Angelman syndrome
Deletions or duplications of the UBE3A gene lead to both Angelman syndrome and some cases of autism, respectively. Studying the effects of altered gene dosage in this region will provide insights into brain defects and suggest targets for therapies for both disorders, says expert Benjamin Philpot.
Insights for autism from Angelman syndrome
By
Benjamin Philpot, Angela Mabb, Matthew Judson
19 July 2011 | 6 min read
Explore more from The Transmitter
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
By
Lauren Schenkman
4 June 2026 | 5 min read
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
By
Brady Huggett
4 June 2026 | 24 min listen
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read